The estimated Net Worth of Robert I Tepper is at least $129 millió dollars as of 23 July 2018. Robert Tepper owns over 266,667 units of Constellation Pharmaceuticals Inc stock worth over $101,393,903 and over the last 11 years he sold CNST stock worth over $27,117,689. In addition, he makes $126,772 as Independent Director at Constellation Pharmaceuticals Inc.
Robert has made over 10 trades of the Constellation Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 266,667 units of CNST stock worth $4,000,005 on 23 July 2018.
The largest trade he's ever made was selling 340,000 units of Constellation Pharmaceuticals Inc stock on 10 January 2014 worth over $7,446,000. On average, Robert trades about 59,062 units every 61 days since 2013. As of 23 July 2018 he still owns at least 2,983,051 units of Constellation Pharmaceuticals Inc stock.
You can see the complete history of Robert Tepper stock trades at the bottom of the page.
Dr. Robert I.Tepper M.D is an Independent Director of the company. Dr. Tepper is a general partner of Third Rock, which he co-founded in March 2007 and focuses on the formation, development and scientific strategy of Third Rock’s portfolio companies, as well as actively identifying and evaluating new investments. Dr. Tepper served as our chief scientific officer from April 2008 to October 2009. Prior to joining Third Rock, Dr. Tepper served as President of Research and Development at Millennium Pharmaceuticals, Inc., or Millennium. Prior to joining Millennium in 1994, he served as principal investigator in the laboratory of tumor biology at the Massachusetts General Hospital Cancer Center. Dr. Tepper is also a founder and former member of the scientific advisory board of Cell Genesys/Abgenix Inc. Dr. Tepper serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several healthcare institutions, including the Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Tufts Medical School. Dr. Tepper serves as a board member of Jounce Therapeutics, Inc., Neon Therapeutics, Inc. and Allena Pharmaceuticals, Inc., each a biopharmaceutical company, and was previously a board member of bluebird bio, Inc. from 2010 to 2015, Kala Pharmaceuticals, Inc. from 2009 to 2018, and Cerulean Pharmaceuticals Inc. from 2006 to 2015. Dr. Tepper is currently a board member of several private life sciences companies. Dr. Tepper holds an A.B. in biochemistry from Princeton University and an M.D. from Harvard Medical School.
As the Independent Director of Constellation Pharmaceuticals Inc, the total compensation of Robert Tepper at Constellation Pharmaceuticals Inc is $126,772. There are 4 executives at Constellation Pharmaceuticals Inc getting paid more, with Jigar Raythatha having the highest compensation of $2,306,720.
Robert's mailing address filed with the SEC is 215 First St Suite 200, Cambridge, MA 02142, USA.
Over the last 15 years, insiders at Constellation Pharmaceuticals Inc have traded over $36,293,867 worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth $88,473,679 . The most active insiders traders include Peter Svennilson, Of The University Of Califo... és Anthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $4,934,940. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth $509,408.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include: